Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 70
Filter
Add more filters

Therapeutic Methods and Therapies TCIM
Publication year range
1.
Biotechnol Prog ; 38(1): e3206, 2022 01.
Article in English | MEDLINE | ID: mdl-34460147

ABSTRACT

The application of biological nanoparticles (NPs) can be considered as a way to overcome the problem of antifungal resistance in pathogenic fungi. This study takes a new approach to biosynthesized NPs influence on the expression of CYP51A and HSP90 antifungal resistance genes in Aspergillus fumigatus and A. flavus, and comparison with antifungal agents. Selenium NPs (Se-NPs) were biosynthesized using Aspergillus strains and their production was proved by several methods including, UV-Vis, XRD, FTIR, FESEM, and EDX techniques. The minimum inhibitory concentrations (MICs) of Aspergillus strains were determined using the CLSI M38-A2 broth microdilution method. The differences in expression levels of CYP51A and HSP90 genes were examined between untreated and treated of A. fumigatus and A. flavus using itraconazole and amphotericin B and biosynthesized Se-NPs through real-time PCR. After confirming the results of NPs synthesis, the MIC of itraconazole and amphotericin B against A. fumigatus and A. flavus was 4 µg/ml. Based on the real-time PCR results, the obtained ∆∆CTs for these strains were -0.18, -1.46, and -1.14. Whereas the MIC values for treated samples with Se-NPs have decreased to 0.5 µg/ml, and the ∆∆CTs for these were -0.25, -1.76, and -1.68. The expression of CYP51A and HSP90 genes was significantly down-regulated through the use of Se-NPs against A. fumigatus and A. flavus.


Subject(s)
Nanoparticles , Selenium , Amphotericin B/pharmacology , Antifungal Agents/pharmacology , Aspergillus/genetics , Aspergillus flavus , Aspergillus fumigatus/genetics , Itraconazole/pharmacology , Microbial Sensitivity Tests , Selenium/pharmacology , Triazoles/pharmacology , Voriconazole/pharmacology
2.
mBio ; 12(4): e0097621, 2021 08 31.
Article in English | MEDLINE | ID: mdl-34399627

ABSTRACT

Aspergillus fumigatus is an important fungal pathogen that causes allergic reactions but also life-threatening infections. One of the most abundant A. fumigatus proteins is Asp f3. This peroxiredoxin is a major fungal allergen and known for its role as a virulence factor, vaccine candidate, and scavenger of reactive oxygen species. Based on the hypothesis that Asp f3 protects A. fumigatus against killing by immune cells, we investigated the susceptibility of a conditional aspf3 mutant by employing a novel assay. Surprisingly, Asp f3-depleted hyphae were killed as efficiently as the wild type by human granulocytes. However, we identified an unexpected growth defect of mutants that lack Asp f3 under low-iron conditions, which explains the avirulence of the Δaspf3 deletion mutant in a murine infection model. A. fumigatus encodes two Asp f3 homologues which we named Af3l (Asp f3-like) 1 and Af3l2. Inactivation of Af3l1, but not of Af3l2, exacerbated the growth defect of the conditional aspf3 mutant under iron limitation, which ultimately led to death of the double mutant. Inactivation of the iron acquisition repressor SreA partially compensated for loss of Asp f3 and Af3l1. However, Asp f3 was not required for maintaining iron homeostasis or siderophore biosynthesis. Instead, we show that it compensates for a loss of iron-dependent antioxidant enzymes. Iron supplementation restored the virulence of the Δaspf3 deletion mutant in a murine infection model. Our results unveil the crucial importance of Asp f3 to overcome nutritional immunity and reveal a new biological role of peroxiredoxins in adaptation to iron limitation. IMPORTANCE Asp f3 is one of the most abundant proteins in the pathogenic mold Aspergillus fumigatus. It has an enigmatic multifaceted role as a fungal allergen, virulence factor, reactive oxygen species (ROS) scavenger, and vaccine candidate. Our study provides new insights into the cellular role of this conserved peroxiredoxin. We show that the avirulence of a Δaspf3 mutant in a murine infection model is linked to a low-iron growth defect of this mutant, which we describe for the first time. Our analyses indicated that Asp f3 is not required for maintaining iron homeostasis. Instead, we found that Asp f3 compensates for a loss of iron-dependent antioxidant enzymes. Furthermore, we identified an Asp f3-like protein which is partially functionally redundant with Asp f3. We highlight an unexpected key role of Asp f3 and its partially redundant homologue Af3l1 in overcoming the host's nutritional immunity. In addition, we uncovered a new biological role of peroxiredoxins.


Subject(s)
Aspergillus fumigatus/genetics , Aspergillus fumigatus/metabolism , Fungal Proteins/metabolism , Iron/metabolism , Peroxiredoxins/genetics , Peroxiredoxins/metabolism , Aspergillosis/microbiology , Aspergillus fumigatus/drug effects , Aspergillus fumigatus/pathogenicity , Female , Fungal Proteins/genetics , Gene Deletion , Gene Expression Regulation, Fungal , Homeostasis , Humans , Iron/pharmacology , Oxidative Stress , Virulence , Virulence Factors/metabolism
3.
Med Mycol ; 59(4): 327-334, 2021 Apr 06.
Article in English | MEDLINE | ID: mdl-32642756

ABSTRACT

The prevalence of azole-resistant Aspergillus fumigatus (ARAF) among chronic pulmonary aspergillosis (CPA) patients treated with azoles in Japan is unknown. The aim of this study was to determine the detection rate of ARAF in isolates from CPA patients who were treated with azoles for varying durations. The potential mechanism of acquiring resistance was examined by sequencing cyp51A and hmg1, two genes associated with ARAF. A. fumigatus isolates (n = 120) were collected from CPA patients (n = 104) between February 2012 and February 2019, at National Hospital Organization Tokyo National Hospital. The isolates were tested for susceptibility to the azole drugs itraconazole (ITCZ) and voriconazole (VRCZ). The detection rate of ARAF among all isolates was 8.3% (n = 10). Of the 10 resistant isolates, eight were ITCZ-resistant and five were VRCZ-resistant. Among 47 isolates obtained from 36 CPA patients who were treated with ITCZ (for an average of 256 days) and/or VRCZ (for an average of 29 days), the resistance rates were 17.0% and 10.6%, respectively. In addition, 46.2% of 13 isolates obtained from CPA patients with ongoing azole treatment at the time of antifungal therapy failure were resistant to azoles. Among the 10 ARAF isolates, a point mutation was detected in cyp51A in seven isolates and in hmg1 in two isolates. ARAF was detected at a high rate in CPA patients, particularly in those with ongoing long-term azole treatment, at the time of azole antifungal therapy failure.


Aspergillus fumigatus can acquire azole resistance during long-term treatment with azole drugs in patients with chronic pulmonary aspergillosis (CPA). The aim of this study was to determine the detection rate of azole-resistant A. fumigatus (ARAF) in isolates from CPA patients who had been treated with azoles. In addition, a potential mechanism of acquiring resistance was examined by sequencing cyp51A and hmg1, two genes associated with ARAF. A. fumigatus isolates (n = 120) were collected from CPA patients (n = 104). The isolates were tested for susceptibility to the azole drugs itraconazole (ITCZ) and voriconazole (VRCZ). The detection rate of ARAF from all isolates was 8.3% (n = 10). Greater than 10% of the 47 isolates obtained from 36 CPA patients who had been treated with azoles exhibited resistance. Furthermore, 46.2% of 13 isolates obtained from CPA patients with ongoing azole treatment at the time of antifungal therapy failure were resistant to azoles. Among the 10 ARAF isolates, a point mutation was detected in cyp51A in seven isolates and in hmg1 in two isolates. ARAF was detected at a high rate in CPA patients undergoing long-term azole treatment at the time of antifungal therapy failure.


Subject(s)
Antifungal Agents/pharmacology , Aspergillus fumigatus/drug effects , Azoles/pharmacology , Azoles/therapeutic use , Drug Resistance, Fungal/genetics , Hospitals/statistics & numerical data , Pulmonary Aspergillosis/drug therapy , Aged , Aspergillus fumigatus/genetics , Azoles/classification , Chronic Disease/therapy , Female , Fungal Proteins/genetics , Genotype , Humans , Male , Microbial Sensitivity Tests , Middle Aged , Prevalence , Pulmonary Aspergillosis/epidemiology , Pulmonary Aspergillosis/microbiology , Retrospective Studies , Tokyo/epidemiology
4.
Environ Sci Pollut Res Int ; 28(3): 3217-3229, 2021 Jan.
Article in English | MEDLINE | ID: mdl-32914303

ABSTRACT

Wastewater treatment plants (WWTPs) can be significant sources of antifungal resistant fungi, which can disseminate further in the environment by getting into rivers together with effluents discharged from WWTPs and pose a risk for human health. In this study, the presence of azole resistance was determined in fungal isolates from treated effluents of two WWTPs using the standard microdilution method from Clinical and Laboratory Standards Institute (CLSI). A total of 41 fungal isolates representing 23 fungal species and 16 fungal genera were obtained. Fungal genera related to the known human and/or plant pathogens such as Aspergillus, Fusarium, and Candida were detected. Among the observed species, the susceptibility of Aspergillus fumigatus and Fusarium oxysporum was tested against fluconazole (FCZ), ketoconazole (KTZ), itraconazole (ITZ), and voriconazole (VCZ). The isolate A. fumigatus was susceptible to KTZ, ITZ, and VCZ, while it showed resistance against FCZ. On the contrast, the isolate F. oxysporum showed resistance to KTZ, ITZ, and VCZ. Comparatively, VCZ showed highest activity against both A. fumigatus and F. oxysporum. Analysis of the gene Cyp51A for the A. fumigatus isolate showed no evidence of drug resistance that could be related to point mutations and/or tandem repeats in the gene. To the best of our knowledge, this is the first susceptibility test study on A. fumigatus and F. oxysporum isolates from the WWTPs of South Africa. In conclusion, this study indicated an urgent need for thorough investigation with larger group of fungal isolates from different regions of South Africa to broadly understand the role of WWTPs in the dissemination of azole antifungal drug resistance.


Subject(s)
Antifungal Agents , Water Purification , Antifungal Agents/pharmacology , Aspergillus fumigatus/genetics , Azoles/pharmacology , Drug Resistance, Fungal , Fungal Proteins , Fungi , Fusarium , Humans , Microbial Sensitivity Tests , South Africa
5.
Enzyme Microb Technol ; 143: 109718, 2021 Feb.
Article in English | MEDLINE | ID: mdl-33375978

ABSTRACT

Epothilones are secondary metabolites produced by Sorangium cellulosum with powerful antiproliferative activity against tumor cells by stabilizing their microtubule arrays, arresting their cellular division at G2-M phase. Unfortunately, the lower yield of epothilone is the challenge for its higher accessibility, thus, searching for alternative sources with promising epothilone producing potency is the prospective. Endophytic fungi are the potential repertoire for bioactive metabolites, thus exploring the epothilone producing potency of endophytic fungi of medicinal plants was objective. Thirty-two fungal isolates were recovered from the tested medicinal plants and their potency to produced epothilone have been assessed using the TLC, HPLC and molecular markers epoA, epoC and epoK. Aspergillus fumigatus EFBL, an endophyte of Catharanthus roseus, was the potent epothilone producer (21.5 µg/g biomass) as revealed from the chromatographic analyses and PCR of molecular markers. The chemical identity of extracted epothilone was verified from the HPLC, NMR, FTIR and LC-MS analyses as epothilone B analogue. The putative epoA gene from A. fumigatus was amplified using RT-PCR with the conservative corresponding primers to the active-sites of S. cellulosum. The amplicons of epoA was 517 bp displayed 98 % similarity with A. fumigatus PKS-NRPS domains, and 40 % similarity with epoA of S. cellulosum. From the in silico analyses, Val506, Ala605 and Ser630 are the conservative amino acids of epoA protein of A. fumigatus and S. cellulosum. Epothilone B from A. fumigatus displayed a strong antiproliferative activity against HepG-2, MCF-7 and LS174 T as revealed from the IC50 values 6.4, 8.7 and 10.21 µM, respectively. The productivity of epothilone B from A. fumigatus was optimized by surface response methodology with Plackett-Burman and Faced Centered Central Composite. With the Plackett-Burman design, the yield of epothilone (54.4-60.1 µg/g biomass) by A. fumigatus was increased by about 2.8-3.0 folds comparing to non-optimized cultures (21.5 µg/ g biomass). From the FCCD design, sucrose, tryptone and incubation time being the highest significant variables medium components affecting the epothilone yield of A. fumigatus. This is the first report exploring the feasibility of endophytic fungi for epothilone producing potency, that could be a novel platform for industrial production of epothilone.


Subject(s)
Catharanthus , Epothilones , Aspergillus fumigatus/genetics , Endophytes/genetics , Prospective Studies
6.
Int J Mol Sci ; 21(20)2020 Oct 16.
Article in English | MEDLINE | ID: mdl-33081273

ABSTRACT

Copper is an essential metal ion that performs many physiological functions in living organisms. Deletion of Afmac1, which is a copper-responsive transcriptional activator in A. fumigatus, results in a growth defect on aspergillus minimal medium (AMM). Interestingly, we found that zinc starvation suppressed the growth defect of the Δafmac1 strain on AMM. In addition, the growth defect of the Δafmac1 strain was recovered by copper supplementation or introduction of the CtrC gene into the Δafmac1 strain. However, chelation of copper by addition of BCS to AMM failed to recover the growth defect of the Δafmac1 strain. Through Northern blot analysis, we found that zinc starvation upregulated CtrC and CtrA2, which encode membrane copper transporters. Interestingly, we found that the conserved ZafA binding motif 5'-CAA(G)GGT-3' was present in the upstream region of CtrC and CtrA2 and that mutation of the binding motif led to failure of ZafA binding to the upstream region of CtrC and upregulation of CtrC expression under zinc starvation. Furthermore, the binding activity of ZafA to the upstream region of CtrC was inversely proportional to the zinc concentration, and copper inhibited the binding of ZafA to the upstream region of CtrC under a low zinc concentration. Taken together, these results suggest that ZafA upregulates copper metabolism by binding to the ZafA binding motif in the CtrC promoter region under low zinc concentration, thus regulating copper homeostasis. Furthermore, we found that copper and zinc interact in cells to maintain metal homeostasis.


Subject(s)
Aspergillus fumigatus/metabolism , Copper/metabolism , Zinc/metabolism , Aspergillus fumigatus/genetics , Aspergillus fumigatus/growth & development , Cation Transport Proteins/genetics , Cation Transport Proteins/metabolism , Copper/deficiency , Fungal Proteins/genetics , Fungal Proteins/metabolism , Gene Expression Regulation, Fungal , Stress, Physiological , Up-Regulation , Zinc/deficiency
7.
Biochem J ; 477(16): 3055-3058, 2020 08 28.
Article in English | MEDLINE | ID: mdl-32845274

ABSTRACT

The answer to the letter 'Absent regulation of iron acquisition by the copper regulator Mac1 in A. fumigatus' has been prepared. We explained our data and showed supplementary information to answer the questions. And we respect the results of other groups first and explain the differences from our results.


Subject(s)
Saccharomyces cerevisiae Proteins , Transcription Factors , Aspergillus fumigatus/genetics , Copper , Homeostasis , Iron , Saccharomyces cerevisiae
8.
mSphere ; 5(4)2020 08 12.
Article in English | MEDLINE | ID: mdl-32817453

ABSTRACT

Aspergillus fumigatus is one of the most common airborne molds capable of causing mycoses and allergies in humans. During infection, fungal surface proteins mediate the first contact with the human immune system to evade immune responses or to induce hypersensitivity. Several methods have been established for surface proteomics (surfomics). Biotinylation coupled with liquid chromatography-tandem mass spectrometry (LC-MS/MS) identification of peptides is a particularly efficient method to identify the surface-exposed regions of proteins that potentially mediate interaction with the host. After biotinylation of surface proteins during spore germination, we detected 231 different biotinylated surface proteins (including several well-known proteins such as RodA, CcpA, and DppV; allergens; and heat shock proteins [HSPs]), as well as some previously undescribed surface proteins. The dynamic change of the surface proteome was illustrated by detection of a relatively high number of proteins exclusively at one developmental stage. Using immunofluorescence microscopy, we confirmed the surface localization of several HSPs of the HSP70 family, which may have moonlighting functions. Collectively, by comparing our data with data representative of previously published A. fumigatus surface proteomes, our study generated a comprehensive data set corresponding to the A. fumigatus surfome and uncovered the surface-exposed regions of many proteins on the surface of conidia or hyphae. These surface-exposed regions are candidates for direct interaction with host cells and may represent antigenic epitopes that either induce protective immune responses or mediate immune evasion. Thus, our data sets provided and compiled here represent reasonable immunotherapy and diagnostic targets for future investigations.IMPORTANCEAspergillus fumigatus is the most important airborne human-pathogenic mold, capable of causing both life-threatening invasive pulmonary aspergillosis in immunocompromised patients and allergy-inducing infections in individuals with atopic allergy. Despite its obvious medical relevance, timely diagnosis and efficient antifungal treatment of A. fumigatus infection remain major challenges. Proteins on the surface of conidia (asexually produced spores) and mycelium directly mediate host-pathogen interaction and also may serve as targets for diagnosis and immunotherapy. However, the similarity of protein sequences between A. fumigatus and other organisms, sometimes even including the human host, makes selection of targets for immunological-based studies difficult. Here, using surface protein biotinylation coupled with LC-MS/MS analysis, we identified hundreds of A. fumigatus surface proteins with exposed regions, further defining putative targets for possible diagnostic and immunotherapeutic design.


Subject(s)
Aspergillosis/diagnosis , Aspergillus fumigatus/chemistry , Fungal Proteins/chemistry , Membrane Proteins/chemistry , Aspergillus fumigatus/genetics , Biomarkers/analysis , Biotinylation , Chromatography, Liquid , Humans , Proteome , Proteomics , Tandem Mass Spectrometry
9.
mBio ; 11(3)2020 05 12.
Article in English | MEDLINE | ID: mdl-32398317

ABSTRACT

Aspergillus fumigatus can cause a variety of lung diseases in immunocompromised patients, including life-threatening invasive aspergillosis. There are only three main classes of antifungal drugs currently used to treat aspergillosis, and antifungal resistance is increasing. Experimental results in fungal biology research are usually obtained as average measurements across whole populations while ignoring what is happening at the single cell level. In this study, we show that conidia with the same genetic background in the same cell population at a similar developmental stage show heterogeneity in their cell wall labeling at the single cell level. We present a rigorous statistical method, newly applied to quantify the level of cell heterogeneity, which allows for direct comparison of the heterogeneity observed between treatments. We show the extent of cell wall labeling heterogeneity in dormant conidia and how the level of heterogeneity changes during germination. The degree of heterogeneity is influenced by deletions of cell wall synthesizing genes and environmental conditions, including medium composition, method of inoculation, age of conidia, and the presence of antifungals. This heterogeneity results in subpopulations of germinating conidia with heterogeneous fitness to the antifungal caspofungin, which targets cell wall synthesis and heterogeneous sensitivity of dormant conidia to phagocytosis by macrophages.IMPORTANCE The fungus Aspergillus fumigatus can cause invasive lung diseases in immunocompromised patients resulting in high mortality. Treatment using antifungal compounds is often unsuccessful. Average population measurements hide what is happening at the individual cell level. We set out to test what impact individual differences between the cell walls of fungal conidia have on their behavior. We show that a population of cells having the same genetic background gives rise to subpopulations of cells that exhibit distinct behavior (phenotypic heterogeneity). This cell heterogeneity is dependent on the strain type, gene deletions, cell age, and environmental conditions. By looking at the individual cell level, we discovered subpopulations of cells that show differential fitness during antifungal treatment and uptake by immune cells.


Subject(s)
Antifungal Agents/pharmacology , Aspergillus fumigatus/drug effects , Aspergillus fumigatus/genetics , Cell Wall/chemistry , Phagocytosis/drug effects , Animals , Drug Resistance, Fungal , Gene Expression Regulation, Fungal , Mice , RAW 264.7 Cells , Single-Cell Analysis , Spores, Fungal/drug effects , Spores, Fungal/genetics
10.
J Mycol Med ; 30(1): 100915, 2020 Apr.
Article in English | MEDLINE | ID: mdl-32008963

ABSTRACT

Aspergillus infections are increasingly recognized as a global health problem because of limited antifungal drugs and occurrence of azole resistance worldwide. More cyp51-mediated and non-cyp51-mediated mechanisms of azole resistance have been identified in clinical and laboratory studies in recent years with applications of molecular biotechnology including next-generation sequencing, reverse genetics and so on. In this review, current research on the molecular mechanisms of azole resistance in A. fumigatus were presented and summarized and meanwhile the putative clinical relevance of these findings from bench work were discussed. Important aims are to gain more insight to mechanism of azole resistance and provide some efficient lead for prevention strategy.


Subject(s)
Antifungal Agents/therapeutic use , Aspergillus fumigatus/genetics , Azoles/therapeutic use , Drug Resistance, Fungal/genetics , Fungal Proteins/genetics , Aspergillosis/genetics , Aspergillosis/microbiology , Aspergillus fumigatus/drug effects , Aspergillus fumigatus/pathogenicity , Gene Expression Regulation, Fungal/drug effects , High-Throughput Nucleotide Sequencing , Humans , Microbial Sensitivity Tests , Mutation , Sterol 14-Demethylase/genetics
11.
Med Mal Infect ; 50(5): 389-395, 2020 Aug.
Article in English | MEDLINE | ID: mdl-31472992

ABSTRACT

Aspergillus fumigatus is the predominant etiological agent of invasive aspergillosis (IA), a difficult-to-manage fungal disease associated with a high case fatality rate. Azole antifungals, particularly voriconazole, have significantly improved the survival rate of patients with IA. However, the clinical advances made possible through the use of medical azoles could be threatened by the emergence of azole-resistant strains which has been reported in an ever-increasing number of countries over the last 10 years. The major resistance mechanism, that combines point mutation(s) in the coding sequence of cyp51A gene and an insertion of a tandem repeat in the promoter region of this gene which leads to its overexpression (TR34/L98H and TR46/Y121F/T289A), is presumed to be of environmental origin. However, the emergence of clinical and environmental azole-resistant strains without the cyp51A gene mutation suggests that other mechanisms could also be responsible for azole resistance (for example, overexpression of efflux pumps). The development of resistance may be linked to either long-term use of azole antifungals in patients with chronic aspergillosis (patient-acquired route) or selection pressure of the fungicides in the environment (environmental route). The fungicide-driven route could be responsible for resistance in azole-naive patients with IA. This literature review aims to summarize recent findings, focusing on the current situation of azole-resistance in A. fumigatus, and provides better understanding of the importance of the environmental route in resistance acquisition.


Subject(s)
Aspergillosis/drug therapy , Aspergillus fumigatus , Azoles/therapeutic use , Drug Resistance, Fungal , Antifungal Agents/therapeutic use , Aspergillosis/microbiology , Aspergillus fumigatus/drug effects , Aspergillus fumigatus/genetics , Aspergillus fumigatus/physiology , Azoles/chemistry , Drug Resistance, Fungal/genetics , Fungal Proteins/genetics , Genotype , Humans , Microbial Sensitivity Tests , Voriconazole/therapeutic use
12.
J Microbiol Biotechnol ; 29(4): 587-595, 2019 Apr 28.
Article in English | MEDLINE | ID: mdl-30786698

ABSTRACT

Pharmacological research on (CHA), a marine-derived quinazolinone alkaloid with significant cytotoxic activity, is restricted by low yields and is a problem that needs to be settled urgently. In this work, the selection of additional nitrogen sources and the optimization of additional concentrations and longer fermentation times using ammonium acetate, were investigated. CHA production was optimized to 62.1 mg/l with the addition of 50 mM ammonium acetate at 120 h of the fermentation in the shaker flask. This feeding strategy significantly increased 3- deoxy-arabino-heptulosonate-7-phosphate synthase activity and transcript levels of critical genes (laeA, dahp and trpC) in the shikimate pathway compared with the non-treatment group. In addition, the selection of the feeding rate (0.01 and 0.03 g/l/h) was investigated in a 5-L bioreactor. As a result, CHA production was increased by 57.9 mg/l with a 0.01 g/l/h ammonium acetate feeding rate. This work shows that the strategy of ammonium acetate supplementation had an effective role in improving CHA production by Aspergillus fumigatus CY018. It also shows that this strategy could serve as an important example of large-scale fermentation of a marine fungus in submerged culture.


Subject(s)
Acetates/pharmacology , Aspergillus fumigatus/drug effects , Aspergillus fumigatus/metabolism , Dietary Supplements , Fermentation , Indole Alkaloids/metabolism , Aspergillus fumigatus/genetics , Batch Cell Culture Techniques/methods , Bioreactors , Culture Media/chemistry , Gene Expression Regulation, Fungal , Genes, Fungal/genetics , Metabolic Networks and Pathways/drug effects , Nitrogen/metabolism , Shikimic Acid/metabolism , Time Factors
13.
Article in English | MEDLINE | ID: mdl-30397071

ABSTRACT

Antifungal agents directed against novel therapeutic targets are required for treating invasive, chronic, and allergic Aspergillus infections. Competitive fitness profiling technologies have been used in a number of bacterial and yeast systems to identify druggable targets; however, the development of similar systems in filamentous fungi is complicated by the fact that they undergo cell fusion and heterokaryosis. Here, we demonstrate that cell fusion in Aspergillus fumigatus under standard culture conditions is not predominately constitutive, as with most ascomycetes, but can be induced by a range of extracellular stressors. Using this knowledge, we have developed a barcode-free genetic profiling system that permits high-throughput parallel determination of strain fitness in a collection of diploid A. fumigatus mutants. We show that heterozygous cyp51A and arf2 null mutants have reduced fitness in the presence of itraconazole and brefeldin A, respectively, and a heterozygous atp17 null mutant is resistant to brefeldin A.


Subject(s)
Antifungal Agents/therapeutic use , Aspergillus fumigatus/drug effects , Brefeldin A/therapeutic use , Cell Fusion/methods , Drug Resistance, Multiple, Fungal/genetics , Itraconazole/therapeutic use , ADP-Ribosylation Factors/genetics , Aspergillosis/drug therapy , Aspergillus fumigatus/genetics , Aspergillus fumigatus/physiology , Cytochrome P-450 Enzyme System/genetics , Fungal Proteins/genetics , Gene Knockout Techniques , Humans , Microbial Sensitivity Tests , Mitochondrial Proton-Translocating ATPases/genetics
14.
Clin Infect Dis ; 68(9): 1463-1471, 2019 04 24.
Article in English | MEDLINE | ID: mdl-30307492

ABSTRACT

BACKGROUND: Triazole resistance is an increasing problem in invasive aspergillosis (IA). Small case series show mortality rates of 50%-100% in patients infected with a triazole-resistant Aspergillus fumigatus, but a direct comparison with triazole-susceptible IA is lacking. METHODS: A 5-year retrospective cohort study (2011-2015) was conducted to compare mortality in patients with voriconazole-susceptible and voriconazole-resistant IA. Aspergillus fumigatus culture-positive patients were investigated to identify patients with proven, probable, and putative IA. Clinical characteristics, day 42 and day 90 mortality, triazole-resistance profiles, and antifungal treatments were investigated. RESULTS: Of 196 patients with IA, 37 (19%) harbored a voriconazole-resistant infection. Hematological malignancy was the underlying disease in 103 (53%) patients, and 154 (79%) patients were started on voriconazole. Compared with voriconazole-susceptible cases, voriconazole resistance was associated with an increase in overall mortality of 21% on day 42 (49% vs 28%; P = .017) and 25% on day 90 (62% vs 37%; P = .0038). In non-intensive care unit patients, a 19% lower survival rate was observed in voriconazole-resistant cases at day 42 (P = .045). The mortality in patients who received appropriate initial voriconazole therapy was 24% compared with 47% in those who received inappropriate therapy (P = .016), despite switching to appropriate antifungal therapy after a median of 10 days. CONCLUSIONS: Voriconazole resistance was associated with an excess overall mortality of 21% at day 42 and 25% at day 90 in patients with IA. A delay in the initiation of appropriate antifungal therapy was associated with increased overall mortality.


Subject(s)
Aspergillus fumigatus/genetics , Autoimmune Diseases/drug therapy , Drug Resistance, Fungal/genetics , Hematologic Neoplasms/drug therapy , Invasive Pulmonary Aspergillosis/drug therapy , Voriconazole/therapeutic use , Adolescent , Adult , Aged , Aged, 80 and over , Antifungal Agents/therapeutic use , Aspergillus fumigatus/drug effects , Aspergillus fumigatus/pathogenicity , Autoimmune Diseases/complications , Autoimmune Diseases/microbiology , Autoimmune Diseases/mortality , Child , Child, Preschool , Female , Hematologic Neoplasms/complications , Hematologic Neoplasms/microbiology , Hematologic Neoplasms/mortality , Humans , Invasive Pulmonary Aspergillosis/complications , Invasive Pulmonary Aspergillosis/microbiology , Invasive Pulmonary Aspergillosis/mortality , Male , Microbial Sensitivity Tests , Middle Aged , Retrospective Studies , Survival Analysis , Time Factors
15.
Article in English | MEDLINE | ID: mdl-29914956

ABSTRACT

A pan-azole-resistant Aspergillus fumigatus strain with the cyp51A mutations Gly138Ser and Asn248Lys was isolated from a patient receiving long-term voriconazole treatment. PCR fragments containing cyp51A with the mutations were introduced along with the Cas9 protein and single guide RNA into the azole-resistant/susceptible strains. Recombinant strains showed increased susceptibility via the replacement of Ser138 by glycine. Genetic recombination, which has been hampered thus far in clinical isolates, can now be achieved using CRISPR/Cas9 genome editing.


Subject(s)
Antifungal Agents/therapeutic use , Aspergillosis/drug therapy , Aspergillus fumigatus/drug effects , Aspergillus fumigatus/genetics , Cytochrome P-450 Enzyme System/genetics , Drug Resistance, Fungal/genetics , Fungal Proteins/genetics , Gene Editing/methods , Voriconazole/therapeutic use , Aged , Aspergillus fumigatus/isolation & purification , CRISPR-Cas Systems/genetics , Humans , Male
16.
J Proteome Res ; 17(2): 780-793, 2018 02 02.
Article in English | MEDLINE | ID: mdl-29251506

ABSTRACT

Calcineurin is a critical cell-signaling protein that orchestrates growth, stress response, virulence, and antifungal drug resistance in several fungal pathogens. Blocking calcineurin signaling increases the efficacy of several currently available antifungals and suppresses drug resistance. We demonstrate the application of a novel scanning quadrupole DIA method for the analysis of changes in the proteins coimmunoprecipitated with calcineurin during therapeutic antifungal drug treatments of the deadly human fungal pathogen Aspergillus fumigatus. Our experimental design afforded an assessment of the precision of the method as demonstrated by peptide- and protein-centric analysis from eight replicates of the study pool QC samples. Two distinct classes of clinically relevant antifungal drugs that are guideline recommended for the treatment of invasive "aspergillosis" caused by Aspergillus fumigatus, the azoles (voriconazole) and the echinocandins (caspofungin and micafungin), which specifically target the fungal plasma membrane and the fungal cell wall, respectively, were chosen to distinguish variations occurring in the proteins coimmunoprecipitated with calcineurin. Novel potential interactors were identified in response to the different drug treatments that are indicative of the possible role for calcineurin in regulating these effectors. Notably, treatment with voriconazole showed increased immunoprecipitation of key proteins involved in membrane ergosterol biosynthesis with calcineurin. In contrast, echinocandin (caspofungin or micafungin) treatments caused increased immunoprecipitation of proteins involved in cell-wall biosynthesis and septation. Furthermore, abundant coimmunoprecipitation of ribosomal proteins with calcineurin occurred exclusively in echinocandins treatment, indicating reprogramming of cellular growth mechanisms during different antifungal drug treatments. While variations in the observed calcineurin immunoprecipitated proteins may also be due to changes in their expression levels under different drug treatments, this study suggests an important role for calcineurin-dependent cellular mechanisms in response to antifungal treatment of A. fumigatus that warrants future studies.


Subject(s)
Aspergillus fumigatus/drug effects , Calcineurin/isolation & purification , Fungal Proteins/isolation & purification , Ribosomal Proteins/isolation & purification , Voriconazole/pharmacology , Antifungal Agents/pharmacology , Aspergillus fumigatus/chemistry , Aspergillus fumigatus/genetics , Aspergillus fumigatus/metabolism , Calcineurin/genetics , Calcineurin/metabolism , Caspofungin , Cell Membrane/chemistry , Cell Membrane/drug effects , Cell Membrane/metabolism , Cell Wall/chemistry , Cell Wall/drug effects , Cell Wall/metabolism , Chromatography, Liquid/methods , Echinocandins/pharmacology , Ergosterol/biosynthesis , Fungal Proteins/genetics , Fungal Proteins/metabolism , Gene Expression , Gene Ontology , Genes, Reporter , Green Fluorescent Proteins/genetics , Green Fluorescent Proteins/metabolism , Immunoprecipitation , Lipopeptides/pharmacology , Micafungin , Molecular Sequence Annotation , Protein Binding , Protein Interaction Mapping , Ribosomal Proteins/genetics , Ribosomal Proteins/metabolism , Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization/methods
17.
Med Mycol ; 56(6): 703-710, 2018 Aug 01.
Article in English | MEDLINE | ID: mdl-29228287

ABSTRACT

No data are available on the in vivo impact of infections with in vitro azole-resistant Aspergillus fumigatus in immunocompetent hosts. Here, the aim was to investigate fungal fitness and treatment response in immunocompetent mice infected with A. fumigatus (parental strain [ps]) and isogenic mutants carrying either the mutation M220K or G54W (cyp51A). The efficacy of itraconazole (ITC) and posaconazole (PSC) was investigated in mice, intravenously challenged either with a single or a combination of ps and mutants (6 × 105 conidia/mouse). Organ fungal burden and clinical parameters were measured. In coinfection models, no fitness advantage was observed for the ps strain when compared to the mutants (M220K and G54W) independent of the presence or absence of azole-treatment. For G54W, M220K, and the ps, no statistically significant difference in ITC and PSC treatment was observed in respect to fungal kidney burden. However, clinical parameters suggest that in particular the azole-resistant strain carrying the mutation G54W caused a more severe disease than the ps strain. Mice infected with G54W showed a significant decline in body weight and lymphocyte counts, while spleen/body weight ratio and granulocyte counts were increased. In immunocompetent mice, in vitro azole-resistance did not translate into therapeutic failure by either ITC or PSC; the immune system appears to play the key role in clearing the infection.


Subject(s)
Antifungal Agents/pharmacology , Aspergillosis/microbiology , Aspergillus fumigatus/drug effects , Azoles/pharmacology , Drug Resistance, Fungal/drug effects , Animals , Antifungal Agents/administration & dosage , Aspergillosis/drug therapy , Aspergillosis/immunology , Aspergillosis/pathology , Aspergillus fumigatus/genetics , Aspergillus fumigatus/pathogenicity , Azoles/administration & dosage , Disease Models, Animal , Drug Resistance, Fungal/genetics , Female , Humans , Itraconazole/administration & dosage , Itraconazole/pharmacology , Lymphocyte Count , Mice , Mice, Inbred BALB C , Microbial Sensitivity Tests , Mutation , Spleen/microbiology , Spleen/pathology , Treatment Outcome , Triazoles/administration & dosage , Triazoles/pharmacology , Virulence
18.
Environ Microbiol ; 20(1): 270-280, 2018 01.
Article in English | MEDLINE | ID: mdl-29124846

ABSTRACT

Emerging azole resistance in Aspergillus fumigatus poses a serious threat to human health. This nationwide surveillance study investigated the prevalence and molecular characteristics of azole-resistant A. fumigatus environmental isolates in Taiwan, an island country with increasing use of azole fungicides. Of the 2760 air and soil samples screened from 2014 to 2016, 451 A. fumigatus isolates were recovered from 266 samples and 34 isolates from 29 samples displayed resistance to medical azoles (itraconazole, voriconazole or posaconazole). The resistance prevalence was 10.9% and 7.5% in A. fumigatus-positive samples and isolates respectively. Most (29, 85.3%) azole-resistant isolates harboured TR34 /L98H mutations, which were widely distributed, clustered genetically with clinical isolates, and had growth rates that were similar to those of the wild-type isolates. Microsatellite genotyping revealed both the global spread of the TR34 /L98H isolates and the occurrence of TR34 /L98H/S297T/F495I isolates belonging to local microsatellite genotypes. AfuMDR3 and atrF, two efflux transporter genes, were constitutively upregulated in two individual resistant isolates without cyp51A mutations, highlighting their potential roles in azole resistance. These results emphasize the need for periodic environmental surveillance at the molecular level in regions in which azole fungicides are applied, and agricultural fungicide management strategies that generate less selective pressure should be investigated.


Subject(s)
Antifungal Agents/therapeutic use , Aspergillosis/drug therapy , Aspergillosis/epidemiology , Aspergillus fumigatus/drug effects , Aspergillus fumigatus/genetics , Azoles/therapeutic use , Drug Resistance, Fungal/genetics , Air Microbiology , Aspergillosis/microbiology , Aspergillus fumigatus/isolation & purification , Cytochrome P-450 Enzyme System/genetics , Fungal Proteins/genetics , Genotype , Humans , Itraconazole/therapeutic use , Microbial Sensitivity Tests , Microsatellite Repeats/genetics , Mutation/genetics , Prevalence , Soil Microbiology , Taiwan/epidemiology , Triazoles/therapeutic use , Voriconazole/therapeutic use
19.
Article in English | MEDLINE | ID: mdl-28743702

ABSTRACT

Patients with hematologic malignancies as well as allogeneic hematopoietic stem cell transplantation (HSCT) patients are at high risk for invasive aspergillosis. Here, we report a culture- and autopsy-proven fatal invasive aspergillosis in an allogeneic HSTC patient which he developed despite posaconazole prophylaxis. The agent was determined to be an azole-resistant Aspergillus fumigatus strain bearing the cyp51A mutation combination TR46 Y121F M172I T289A. At increasing frequency, the azole resistance of A. fumigatus is being reported globally, limiting treatment options and complicating regimens.


Subject(s)
Antifungal Agents/therapeutic use , Aspergillus fumigatus/drug effects , Aspergillus fumigatus/genetics , Azoles/therapeutic use , Cytochrome P-450 Enzyme System/genetics , Drug Resistance, Multiple, Fungal/genetics , Fungal Proteins/genetics , Invasive Pulmonary Aspergillosis/drug therapy , Aged , Alleles , Amphotericin B/therapeutic use , Caspofungin , Echinocandins/therapeutic use , Humans , Invasive Pulmonary Aspergillosis/microbiology , Leukemia, Myeloid, Acute/microbiology , Lipopeptides/therapeutic use , Male , Microbial Sensitivity Tests , Mutation/genetics , Treatment Outcome , Triazoles/therapeutic use , Voriconazole/therapeutic use
20.
Clin Infect Dis ; 64(1): 76-78, 2017 Jan 01.
Article in English | MEDLINE | ID: mdl-27682064

ABSTRACT

A case of fatal aspergillosis due to a TR46/Y121F/T289A azole-resistant Aspergillus fumigatus is reported. Environmental investigations at the patient's residence led to the recovery of TR46/Y121F/T289A isolates, genotypically indistinguishable from the clinical isolate, supporting for the first time the direct role of household as potential source of azole-resistant invasive aspergillosis.


Subject(s)
Antifungal Agents/therapeutic use , Aspergillosis/drug therapy , Aspergillosis/etiology , Aspergillus fumigatus/drug effects , Azoles/therapeutic use , Drug Resistance, Fungal , Immunocompromised Host , Aged , Antifungal Agents/pharmacology , Arthritis, Rheumatoid/complications , Arthritis, Rheumatoid/drug therapy , Aspergillus fumigatus/genetics , Azoles/pharmacology , Cytochrome P-450 Enzyme System/genetics , Fatal Outcome , Fungal Proteins/genetics , Humans , Infliximab/adverse effects , Infliximab/therapeutic use , Microbial Sensitivity Tests , Mutation
SELECTION OF CITATIONS
SEARCH DETAIL